^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN panel also recommends subsequent chemotherapy options including pemetrexed...vinorelbine, or gemcitabine...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    CONTRADICTING EVIDENCE:...Recommendations...Systemic therapy for second line and beyond…Single-agent gemcitabine or vinorelbine [II, B] have limited second-line activity, as suggested by ORRs or OS, with encouraging activity for gemcitabine–ramucirumab combination [III, C]. Recommendations...First-line systemic therapy...Maintenance gemcitabine is not routinely recommended in patients with non progressive MPM...
    DOI:
    https://doi.org/10.1016/j.annonc.2021.11.005